The miR-15 family acts as a novel regulator of cardiac hypertrophy and fibrosis through inhibition of the TGFβ-pathway, suggesting a potential therapeutic target.
Potential target in hypertrophy via TGFβ; leaves open translation from animal data.
We identified the miR-15 family as a novel regulator of cardiac hypertrophy and fibrosis acting by inhibition of the TGFβ-pathway.
No takes yet. Share an insight, caveat, or question.
Tijsen et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: